
    
      Approximately 224 adults will be enrolled in an outpatient Phase III study to compare the
      safety and efficacy of topically applied magainin peptide (MSI-78) to that of ofloxacin
      (FLOXIN, Ortho-McNeil Pharmaceutical Corporation) an oral fluoroquinolone antibiotic, in the
      treatment of infected diabetic foot ulcers.

      This is a randomized, controlled, double-blind trial that will involve twenty or more
      clinical centers.
    
  